Published in AAPS PharmSciTech on December 21, 2007
Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech (2008) 1.00
Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen eight-stage cascade impactor (ACI). AAPS PharmSciTech (2012) 0.83
Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations. Int J Nanomedicine (2011) 0.83
New surface radiolabeling schemes of super paramagnetic iron oxide nanoparticles (SPIONs) for biodistribution studies. Nanoscale (2015) 0.79
Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing. AAPS PharmSciTech (2014) 0.78
Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications. AAPS PharmSciTech (2013) 0.78
The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols. AAPS PharmSciTech (2013) 0.77
Investigation of dry powder inhaler (DPI) resistance and aerosol dispersion timing on emitted aerosol aerodynamic particle sizing by multistage cascade impactor when sampled volume is reduced from compendial value of 4 L. AAPS PharmSciTech (2014) 0.75
Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree. J Aerosol Med (2003) 3.62
Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med (1998) 2.96
Standardization of inhalation provocation tests: two techniques of aerosol generation and inhalation compared. Am Rev Respir Dis (1981) 2.75
Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med (2003) 2.75
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med (2005) 2.43
Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax (1996) 2.00
The importance of particle size in response to inhaled bronchodilators. Eur J Respir Dis Suppl (1982) 1.80
Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: background for a statistical method. AAPS PharmSciTech (2007) 1.78
Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr Pulmonol (1998) 1.73
Analysis of cascade impactor mass distributions. J Aerosol Med (2005) 1.73
The influence of lung deposition on clinical response. J Aerosol Med (2001) 1.73
Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: part 2--evaluation of a method for determining equivalence. AAPS PharmSciTech (2007) 1.69
Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med (2005) 1.69
Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation. J Allergy Clin Immunol (1981) 1.66
Problems with inhaler use: a call for improved clinician and patient education. Respir Care (2005) 1.64
The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis (1978) 1.48
Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol (1999) 1.44
New perspectives on inhaled drug delivery and systemic bioactivity. Thorax (1995) 1.43
In vitro comparison of salbutamol hydrofluoroalkane (Airomir) metered dose inhaler aerosols inhaled during pediatric tidal breathing from five valved holding chambers. J Aerosol Med (1999) 1.42
Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. Thorax (1986) 1.42
Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence. AAPS PharmSciTech (2007) 1.42
Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. Chest (1989) 1.41
Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design. J Aerosol Med (2003) 1.34
The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems. J Aerosol Med (1998) 1.20
Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration. J Aerosol Med (2003) 1.18
Is the flow rate used to drive a jet nebuliser clinically important? Br Med J (Clin Res Ed) (1985) 1.15
The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbuhaler). Eur Respir J (1989) 1.13
Aerosol penetration into the lung; influence on airway responses. Chest (1981) 1.13
In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med (1995) 1.12
Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm (2000) 1.09
Why particle size should affect clinical response to inhaled therapy. J Aerosol Med (2001) 1.07
Revised internal volumes of cascade impactors for those provided by mitchell and nagel. J Aerosol Med (2005) 1.05
Effect of inhaled terbutaline sulphate in relation to its deposition in the lungs. Pulm Pharmacol (1992) 1.05
Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers. Can Respir J (2004) 1.02
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol (1985) (2003) 1.02
How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med (1998) 0.94
The Sophia Anatomical Infant Nose-Throat (Saint) model: a valuable tool to study aerosol deposition in infants. J Aerosol Med (2001) 0.93
Impact of oropharyngeal deposition on inhaled dose. J Aerosol Med (1998) 0.92
Is driving gas flow rate clinically important for nebulizer therapy? Br J Dis Chest (1986) 0.91
A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma. Br J Dis Chest (1986) 0.91
A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm (1999) 0.89
Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. Thorax (1987) 0.89
The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. J Pharm Sci (2005) 0.88
The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. J Allergy Clin Immunol (1998) 0.87
A personal cascade impactor: design, evaluation and calibration. Am Ind Hyg Assoc J (1987) 0.87
Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J Aerosol Med (2006) 0.86
Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care (2000) 0.83
An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol. Int J Pharm (2004) 0.78
Design of facemasks for delivery of aerosol-based medication via pressurized metered dose inhaler with valved holding chamber: key issues that affect performance. J Aerosol Med (2007) 0.78
An evaluation of two aerosol delivery systems for rhDNase. Eur Respir J (1997) 0.78
Physical properties and clinical efficacy of two sodium cromoglycate inhalation aerosol preparations. Acta Pharm Nord (1991) 0.77
Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy. Int J Pharm (2002) 0.77
Laboratory evaluation of metered-dose inhalers with models that simulate interaction with the patient. Respir Care Clin N Am (2001) 0.77
The preferential deposition of inhaled isoproterenol and propranolol in asthmatic patients. Chest (1981) 0.76
In vitro inhalation behaviour and therapeutical response of salbutamol particles administered from two metered dose aerosols. Pharmazie (1991) 0.76
Albuterol aerosol delivered via metered-dose inhaler to intubated pediatric models of 3 ages, with 4 spacer designs. Respir Care (2003) 0.76
Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology (2012) 3.30
Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med (2005) 1.69
Responsiveness to three bronchial provocation tests in patients with asthma. Chest (2003) 1.49
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. J Pharm Sci (2006) 1.18
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci (2004) 1.17
In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv (2008) 1.15
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int J Pharm (2010) 1.11
Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev (2010) 1.11
Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res (2005) 1.10
How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res (2005) 1.08
Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med (2002) 1.06
Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv (2010) 1.05
What is a suitable dissolution method for drug nanoparticles? Pharm Res (2008) 1.01
Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulm Pharmacol Ther (2004) 1.00
Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration. Int J Pharm (2012) 0.99
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm (2008) 0.98
Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev (2011) 0.98
Electrostatic charge characteristics of aerosols produced from metered dose inhalers. J Pharm Sci (2005) 0.97
The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res (2005) 0.97
Coughing during mannitol challenge is associated with asthma. Chest (2004) 0.95
Liposomal formulations for inhalation. Ther Deliv (2013) 0.94
A simple relationship between dielectric constant of mixed solvents with solvent composition and temperature. Int J Pharm (2004) 0.94
Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects. Respirology (2005) 0.94
SPECT Imaging for Radioaerosol Deposition and Clearance Studies. J Aerosol Med (2006) 0.92
The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci (2008) 0.92
Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Pharm Res (2007) 0.91
Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res (2007) 0.91
The rejuvenated pressurised metered dose inhaler. Expert Opin Drug Deliv (2007) 0.90
Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res (2010) 0.90
Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci (2005) 0.89
Effect of powder polydispersity on aerosol generation. J Pharm Pharm Sci (2002) 0.89
Deposition, imaging, and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv (2010) 0.88
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics. Eur J Pharm Biopharm (2007) 0.87
Inhaled antibiotics to treat lung infection. Pharm Pat Anal (2013) 0.87
Solubility prediction in supercritical CO(2) using minimum number of experiments. J Pharm Sci (2002) 0.87
Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci (2008) 0.86
Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®). AAPS J (2013) 0.86
Modifying the release properties of liposomes toward personalized medicine. J Pharm Sci (2014) 0.86
Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest (2003) 0.86
The use of computational approaches in inhaler development. Adv Drug Deliv Rev (2011) 0.86
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci (2010) 0.84
Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci (2011) 0.84
Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers? Pharm Res (2012) 0.84
Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. J Pharm Biomed Anal (2009) 0.84
Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties. AAPS PharmSciTech (2014) 0.83
Recent advances in controlled release pulmonary therapy. Curr Drug Deliv (2009) 0.83
Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci (2010) 0.83
Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). Eur J Pharm Sci (2009) 0.83
The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med (2002) 0.82
Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci (2008) 0.82
The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci (2007) 0.82
Management of retrobulbar hematoma. Am J Rhinol (2008) 0.81
Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm (2007) 0.81
Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J Pharm Sci (2009) 0.80
Electrostatics of pharmaceutical inhalation aerosols. J Pharm Pharmacol (2009) 0.80
Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. J Pharm Sci (2011) 0.80
Electrostatics in pharmaceutical aerosols for inhalation. Ther Deliv (2013) 0.80
Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther Deliv (2010) 0.80
Lactose composite carriers for respiratory delivery. Pharm Res (2008) 0.80
Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv (2012) 0.80
Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler. J Aerosol Med Pulm Drug Deliv (2013) 0.80
A solid-state NMR study of protein mobility in lyophilized protein-sugar powders. J Pharm Sci (2002) 0.80
Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int J Pharm (2012) 0.79
Impact angles as an alternative way to improve aerosolisation of powders for inhalation? Eur J Pharm Sci (2010) 0.79
Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm (2004) 0.79
Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols. Pharm Res (2007) 0.79
Effect of crystallinity on electrostatic charging in dry powder inhaler formulations. Pharm Res (2014) 0.78
Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying. Pharm Res (2013) 0.78
Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance. J Aerosol Med Pulm Drug Deliv (2012) 0.78
Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles. AAPS J (2009) 0.78
Multi-scale modelling of powder dispersion in a carrier-based inhalation system. Pharm Res (2014) 0.78
Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance. J Pharm Sci (2011) 0.78
Powder Production and Particle Engineering for Dry Powder Inhaler Formulations. Curr Pharm Des (2015) 0.78
Electrostatic charge characteristics of jet nebulized aerosols. J Aerosol Med Pulm Drug Deliv (2010) 0.78
The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems. Pharm Res (2010) 0.78
Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. Ther Deliv (2013) 0.78
Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm (2010) 0.77
Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int J Pharm (2006) 0.77
The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Drug Dev Ind Pharm (2013) 0.77
Solubility prediction of paracetamol in binary and ternary solvent mixtures using Jouyban-Acree model. Chem Pharm Bull (Tokyo) (2006) 0.77
Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. Int J Pharm (2013) 0.77
Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm Res (2010) 0.77
Inhalation challenge with bovine dander allergens: who needs it? Chest (2003) 0.77
Method to introduce mannitol powder to intubated patients to improve sputum clearance. J Aerosol Med Pulm Drug Deliv (2010) 0.77
Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci (2008) 0.77
TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine (2013) 0.77
Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech (2014) 0.77
Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm (2011) 0.77
Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. Pharm Res (2008) 0.76
Nanodrug particles and nanoformulations for drug delivery. Adv Drug Deliv Rev (2011) 0.76
A novel inhalable form of rifapentine. J Pharm Sci (2014) 0.76
Does electrostatic charge affect powder aerosolisation? J Pharm Sci (2010) 0.76
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci (2009) 0.76
Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system. Pharm Res (2003) 0.76
Evaluation on the use of confined liquid impinging jets for the synthesis of nanodrug particles. Drug Dev Ind Pharm (2008) 0.76
The effects of newer antidepressants on low-density lipoprotein cholesterol levels. J Clin Psychiatry (2004) 0.76
Pulmonary drug delivery. Ther Deliv (2013) 0.76
Unitary hormonal models, peripheral markers, and evaluation of response to drug: a response to Weisman and Feldman. Psychoneuroendocrinology (2013) 0.75
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy. J Pharm Sci (2014) 0.75
The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. Pharm Res (2009) 0.75